OncoMatch/Clinical Trials/NCT06547840
A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer
Is NCT06547840 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies MOv18 IgE for advanced ovarian cancer.
Treatment: MOv18 IgE — EPS101-10-02 is a Phase Ib open label, multicentre clinical trial comprising of a Dose Escalation phase (Part 1) followed by a Dose Expansion phase (Part 2) of MOv18 IgE in patients with folate receptor alpha-expressing (5% or higher) platinum resistant ovarian cancer The dose escalation part of the study will primarily assess the safety and tolerability of MOv18 IgE in ascending dose cohorts, until the determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD). Part 2 (dose expansion) will further assess the safety, tolerability and anti-tumour activity of MOv18 IgE.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Required: FOLR1 overexpression (1+, 2+ or 3+ membrane staining on at least 5% of tumour cells by immunohistochemistry using the BN3.2 antibody)
Tumour tissue expressing FRα (1+, 2+ or 3+ membrane staining on at least 5% of tumour cells by immunohistochemistry using the BN3.2 antibody (Leica Biosystems))
Disease stage
Grade: high-grade serousendometrioidpredominantly serous/endometrioid component
measurable disease as defined by RECIST v1.1 on CT or MRI scan with at least one lesion that is accessible by image-guided biopsy and which is not a target lesion
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy (carboplatin, paclitaxel)
Platinum-free interval since last line of platinum of less than 6 months (182 days)
Lab requirements
Blood counts
ANC ≥1.5 × 10^9/L (>1,500/mm3) without G-CSF/GM-CSF; Platelets ≥100 × 10^9/L (>100,000 per mm3); Haemoglobin >9 g/dL (stable for at least 1 week post-transfusion if transfused); Lymphocyte count ≥1000 cells/mm3 (1.0x10^9/L); Adequate coagulation: PT ≤1.5 × ULN or INR <1.5 and aPTT ≤1.5 × ULN (does not apply to patients on a stable anticoagulant dose within 28 days prior to first dose).
Kidney function
Creatinine or measured and calculated creatinine clearance (eGFR can also be used in place of creatinine or creatinine clearance) ≤1.5 × ULN, or ≥60 mL/min for a patient with creatinine levels >1.5 × institutional ULN.
Liver function
Serum total bilirubin ≤1.5 × ULN or direct bilirubin ≤ ULN for a patient with total bilirubin levels >1.5 × ULN. AST (SGOT) and ALT (SGPT) ≤2.5 × ULN or ≤5 × ULN for a patient with liver metastases. Albumin ≥3.0 g/dL.
Adequate haematological function, including all of the following: ... Adequate coagulation function at screening ... Adequate renal function ... Adequate hepatic function ...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify